-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positiv ...

Arvinas, Inc. (ARVN) shares soared 10% in the last trading session to close at $45.65. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.The sudden surge in the stock price can be attributed to the positive mindset of the investors regarding Arinivas' pipeline progress. The company is currently evaluating its lead candidate, vepdegestrant (formerly ARV-471) in two late-stage studies — VERITAC-2 an ...

NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference on Wednesday, February 7 at 10:30 a.m. ET in New York. A live audio webcast of the presentat ...

Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC Discovery Engine platform [2] - The company aims to improve the lives of patients with debilitating and life-threatening diseases through the discovery, development, and commercialization of these therapies [2] Clinical Programs - Arvinas has a robust preclinical pipeline of PROTAC protein degraders targeting both validated and "undruggable" targets [2] - The company is advancing three investigational clinical-stage programs: - Vepdegestrant (ARV-471) for locally advanced or metastatic ER+/HER2- breast cancer - ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer [2] Upcoming Events - Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference on February 7, 2024 [1] - A live audio webcast of the presentation will be available on the company's website [1]

Investors might want to bet on Arvinas, Inc. (ARVN) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...

Company Announcement - Arvinas, Inc announced the appointment of Jared Freedberg as General Counsel, bringing over 20 years of legal and commercial experience to the company [1] - Jared Freedberg's previous roles include General Counsel at Intercept Pharmaceuticals and Immunomedics, Inc, as well as Vice President, Legal, Business Development and Licensing at Mallinckrodt Pharmaceuticals [1] - The company granted Mr Freedberg an option to purchase 67,314 shares of common stock and a restricted stock unit award for 45,504 shares as part of his employment inducement [2] Executive Compensation - The stock option has a 10-year term with an exercise price of $38.10 per share, equal to the closing price on the grant date [3] - The option vests over four years, with 25% vesting after one year and the remainder vesting monthly thereafter [3] - The restricted stock units vest in four equal annual installments, contingent on continued employment [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC Discovery Engine platform [4] - The company has three clinical-stage programs: vepdegestrant (ARV-471) for ER+/HER2- breast cancer, and ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer [4] Strategic Focus - The company aims to advance its pipeline of earlier stage assets driven by the PROTAC protein degrader platform while preparing for potential product commercialization [1] - Arvinas is pioneering scientific advancements in protein degradation to improve treatment options for patients with serious diseases [2][4]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 ________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 _______________ ...

Pioneering the future of targeted protein egradation therapeutics d Safe harbor and forward-looking statements ...